PARP1 and ischemia reperfusion injury: The PARP inhibitor PJ34 has a beneficial effect in several experimental models of ischemia-reperfusion injury [27,28,29], including in our liver IRI model; administration of P34 to wild-type mice at reperfusion lowered the AST levels in these mice post-IRI (Fig 8A).